|
Indications and Dosage
Subcutaneous
Plaque psoriasis Adult: For moderate to severe cases in patients who are candidates for systemic treatment or phototherapy: Initially, 150 mg (2 consecutive 75 mg inj) at week 0 and week 4, then every 12 weeks thereafter. If there is no response after 16 weeks, may consider treatment discontinuation.
|
|
Contraindications
Hypersensitivity. Clinically important active infection (e.g. active TB). Concomitant use of live vaccines.
|
|
Special Precautions
Patient with history of chronic or recurrent infections, and risk factors for infection. Consider anti-TB therapy before initiation in patients with history of latent or active TB whom adequate course of TB treatment is unconfirmed. Completion of all appropriate immunisations may be considered based on current guidelines prior to initial therapy (refer to local treatment guidelines or detailed product information). Pregnancy and lactation.
|
|
Adverse Reactions
Significant: Infections (e.g. upper respiratory tract infections, tinea infections), serious hypersensitivity reactions (e.g. anaphylaxis).
General disorders and administration site conditions: Fatigue, asthenia; inj site reactions (e.g. erythema, irritation, haematoma, haemorrhage, pruritus, pain). Nervous system disorders: Headache. Skin and subcutaneous tissue disorders: Pruritus. |
|
Monitoring Parameters
Perform TB screening before initiation and during treatment (chest X-ray if TB positive); hepatitis B or C virus and HIV screening prior to starting therapy. Monitor CBC with differential and complete metabolic panel at baseline; signs and symptoms of infection and active TB during and after treatment.
|
|
Drug Interactions
Potentially Fatal: May enhance the adverse or toxic effects of live vaccines.
|
|
Action
Description:
Mechanism of Action: Risankizumab is a human immunoglobulin G1 (IgG1) monoclonal antibody that selectively binds to the p19 subunit of interleukin 23 (IL-23) cytokine, thereby blocking its interaction with IL-23 receptor and leading to the inhibition of the release of proinflammatory cytokines and chemokines. Pharmacokinetics: Absorption: Bioavailability: Approx 89%. Time to peak plasma concentration: 3-14 days. Distribution: Volume of distribution: Approx 11.2 L. Metabolism: Expected to undergo degradation via catabolic pathways into small peptides and amino acids. Excretion: Elimination half-life: Approx 28 days. |
|
Storage
Store between 2-8°C. Do not freeze. Protect from light.
|
|
ATC Classification
L04AC18 - risankizumab ; Belongs to the class of interleukin inhibitors. Used as immunosuppressants.
|
|
References
Anon. Risankizumab-rzaa. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 04/02/2021. Anon. Risankizumab. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 04/02/2021. Buckingham R (ed). Risankizumab. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 04/02/2021. Joint Formulary Committee. Risankizumab. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 04/02/2021. Skyrizi (AbbVie, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 04/02/2021. Skyrizi 75 mg Solution for Injection in Pre-filled Syringe (AbbVie Deutschland GmbH & Co. KG). European Medicines Agency [online]. Accessed 04/02/2021. Skyrizi 75 mg Solution for Injection in Pre-filled Syringe (AbbVie Sdn Bhd). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 04/02/2021.
|
Sign Out
